ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
69 announcements with these filters
Biocon Limited's Board will meet on May 07, 2026, to consider a preferential allotment of equity shares. This issuance is intended to fund the acquisition of equity shares in its material subsidiary, Biocon Biologics Limited, for consideration other than cash. The transaction is subject to shareholder approval via postal ballot.
Biocon Limited announced that the U.S. FDA completed a Pre-License Inspection at its Bengaluru biosimilars site. The inspection concluded with five procedural observations. The company plans to submit a corrective action plan and does not expect any impact on data integrity or quality oversight.
Biocon Limited confirmed the full utilization of ₹200 Crore raised through Commercial Papers for the quarter ended March 31, 2026. The funds were deployed for subsidiary equity acquisition and debt redemption. The company reported no deviation in fund usage and fulfilled all payment obligations by January 30, 2026.
Biocon Limited has scheduled a Board Meeting on May 7, 2026, to consider audited standalone and consolidated financial results for the year ended March 31, 2026. The board will also consider a recommendation for a final dividend. The trading window for designated persons remains closed until May 9, 2026.
Biocon Ltd will hold a Board Meeting on May 07, 2026, to approve audited financial results for the fiscal year ended March 31, 2026, and recommend a dividend. An earnings conference call is scheduled for May 08, 2026. The trading window for designated persons remains closed until May 09, 2026.
Biocon Limited received Health Canada approval for its biosimilars Bosaya and Vevzuo, marking its entry into the Canadian denosumab market. The approval targets osteoporosis and cancer-related bone conditions, potentially benefiting over 2 million patients. This milestone strengthens Biocon's global biosimilars portfolio across immunology and oncology.
Biocon Pharma, a subsidiary of Biocon Limited, received U.S. FDA approval for Dapagliflozin Tablets (5 mg and 10 mg) for treating type 2 diabetes. The product will be manufactured at Biocon's FDA-approved facilities. This approval strengthens Biocon's global diabetes portfolio, covering oral solids, biosimilar insulins, and GLP-1 peptides.
Biocon Limited submitted a compliance certificate under SEBI Regulations for the quarter ended March 31, 2026. The certificate confirms that security certificates received for dematerialization were processed and mutilated by the Registrar, KFin Technologies Limited. This is a routine quarterly disclosure with no direct financial impact.
Biocon Limited has commercially launched Bosaya and Aukelso, its interchangeable denosumab biosimilars, in the United States. These products target the $5 billion U.S. market for osteoporosis and bone metastasis treatments. This strategic expansion strengthens Biocon's global biosimilars portfolio and provides affordable treatment options for over 10 million patients.